Vallon Plunges 74% After Disappointing Study Results for ADHD Treatment
(VallonPharma) Shares of Vallon Pharmaceuticals Inc. fell more than 74% in pre-market on Monday after a weak study outcome for Lead Program, ADAIR, for ADHD treatment. Vallon said that the…